Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — November 2013

Planlagt Fastgjort Låst Flyttet Genmab
226 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • investor1989I Offline
    investor1989I Offline
    investor1989
    wrote on sidst redigeret af
    #202

    Just a moment...

    favicon

    (www.proinvestor.com)

    1 Reply Last reply
    0
    • S Offline
      S Offline
      stoft
      wrote on sidst redigeret af
      #203

      Det blir dejlig af være genmab aktionær idag 🙂

      1 Reply Last reply
      0
      • JørgenVarnæsJ Offline
        JørgenVarnæsJ Offline
        JørgenVarnæs
        wrote on sidst redigeret af
        #204

        Der bliver varmet om til ASH og det store showdown i CLL markedet - her er lidt baggrund på de forskellige spillere: http://seekingalpha.com/article/1860201-gilead-vs-johnson-johnson-roche-in-blood-cancer-showdown?source=yahoo

        1 Reply Last reply
        0
        • MadsSkjernM Offline
          MadsSkjernM Offline
          MadsSkjern
          wrote on sidst redigeret af
          #205

          CLL, competitive landscape. Arzerra er godt med i kombi med ibrutinib og idelalisib https://twitter.com/zDonShimoda/status/405007
          519640064000/photo/1/large

          1 Reply Last reply
          0
          • MadsSkjernM Offline
            MadsSkjernM Offline
            MadsSkjern
            wrote on sidst redigeret af
            #206

            https://twitter.com/zDonShimoda/status/405007519640064000/photo/1/large

            1 Reply Last reply
            0
            • JørgenVarnæsJ Offline
              JørgenVarnæsJ Offline
              JørgenVarnæs
              wrote on sidst redigeret af
              #207

              ja, det bliver lidt af et landskab at fylde ud. Arzerra + alkylator er ikke taget med i opgørelsen.

              1 Reply Last reply
              0
              • investor1989I Offline
                investor1989I Offline
                investor1989
                wrote on sidst redigeret af
                #208

                "
                This has made some investors nervous. Michael Yee of RBC Capital Markets speculates that the FDA is waiting for data from the ongoing Resonate trial in January which compares Imbruvica to Arzerra, a drug made by GlaxoSmithKline (GSK)."

                1 Reply Last reply
                0
                • investor1989I Offline
                  investor1989I Offline
                  investor1989
                  wrote on sidst redigeret af
                  #209

                  Var faktisk ikke klar over at vi fik sådanne data

                  1 Reply Last reply
                  0
                  • investor1989I Offline
                    investor1989I Offline
                    investor1989
                    wrote on sidst redigeret af
                    #210

                    Gazyva comes with a boxed warning about the possibility that the Hepatitis B virus could reactivate and it could cause PML (progressive multifocal leukoencephalopathy). PML is a rare brain disorder that damages the material which protects the nerves in the brain.

                    1 Reply Last reply
                    0
                    • investor1989I Offline
                      investor1989I Offline
                      investor1989
                      wrote on sidst redigeret af
                      #211

                      lyder hyggeligt 🙂

                      1 Reply Last reply
                      0
                      • G Offline
                        G Offline
                        gentogen
                        wrote on sidst redigeret af
                        #212

                        BendOfa refractory CLL: The overall response rate (ORR), as per intention-to-treat analysis, was 72.3% (95% CI, 57–84%), with 17% complete responses. After a median follow-up of 24.2 months, the overall survival was 83.6% (95% CI, 73.0–95.7%) and the progression-free survival (PFS) 49.6% (95% CI, 35.9–68.6%). The median PFS was 23.6 months.

                        1 Reply Last reply
                        0
                        • G Offline
                          G Offline
                          gentogen
                          wrote on sidst redigeret af
                          #213

                          BendOfa is feasible and effective in relapsed/refractory CLL patients, including patients with high risk clinical and biological features.

                          1 Reply Last reply
                          0
                          • G Offline
                            G Offline
                            gentogen
                            wrote on sidst redigeret af
                            #214

                            accepted article preview 13 November 2013; doi: 10.1038/leu.2013.334 http://www.nature.com/leu/journal/vaop/naam/abs/leu2013334a.html

                            1 Reply Last reply
                            0
                            • JørgenVarnæsJ Offline
                              JørgenVarnæsJ Offline
                              JørgenVarnæs
                              wrote on sidst redigeret af
                              #215

                              Ja - arzerra er ikke helt uden virkning

                              1 Reply Last reply
                              0
                              • celsiusC Offline
                                celsiusC Offline
                                celsius
                                wrote on sidst redigeret af
                                #216

                                Gentogen: og så på dansk -:)

                                1 Reply Last reply
                                0
                                • celsiusC Offline
                                  celsiusC Offline
                                  celsius
                                  wrote on sidst redigeret af
                                  #217

                                  Gentogen: jeg er bare ein dumme dänen -:)

                                  1 Reply Last reply
                                  0
                                  • SolsenS Offline
                                    SolsenS Offline
                                    Solsen
                                    wrote on sidst redigeret af
                                    #218

                                    Det er jo resultater på linie med frontline - ganske pænt i refrac !!!

                                    1 Reply Last reply
                                    0
                                    • JørgenVarnæsJ Offline
                                      JørgenVarnæsJ Offline
                                      JørgenVarnæs
                                      wrote on sidst redigeret af
                                      #219

                                      det eneste problem med de resultater er efterhånden, at CR er lidt for høj....

                                      1 Reply Last reply
                                      0
                                      • JørgenVarnæsJ Offline
                                        JørgenVarnæsJ Offline
                                        JørgenVarnæs
                                        wrote on sidst redigeret af
                                        #220

                                        vi fik vist ikke markeret denne - http://seekingalpha.com/currents/post/1410482 det er btd kandidat nr 2, der bliver godkendt

                                        1 Reply Last reply
                                        0
                                        • SolsenS Offline
                                          SolsenS Offline
                                          Solsen
                                          wrote on sidst redigeret af
                                          #221

                                          Vi har haft den på radaren

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger